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Evidence for genetic heterogeneity in Dent’s disease.
Background. Dent’s disease (X-linked nephrolithiasis) is a
proximal tubulopathy that has been consistently associated with
inactivating mutations in the CLCN5 gene encoding the ClC-5
chloride channel expressed in tubular epithelial cells.
Methods. We performed mutation analysis of the coding re-
gion of CLCN5 by DNA sequencing in 32 unrelated males, all of
whom met the following three clinical criteria for the diagnosis
of Dent’s disease: (1) low-molecular-weight (LMW) protein-
uria; (2) hypercalciuria; and (3) at least one of the following:
nephrocalcinosis, kidney stones, renal insufficiency, hypophos-
phatemia, or hematuria.
Results. Sixteen mutations (ten missense, four nonsense, two
frameshift) were found in 19 patients. Mutations were con-
firmed by restriction analysis or allele-specific polymerase chain
reaction (PCR), segregated with disease in the families, and
were not polymorphisms. In the other 13 patients with Dent’s
disease, the coding sequence of CLCN5 was normal. In these
13 patients, we also sequenced two regions of the CLCN5 pro-
moter (626 and 586 bp, respectively, 2.1 and 1 kb upstream of
exon 2) containing regulatory sites [activating protein-1 (AP-
1)-like, AP-4, and cyclic adenosine monophosphate (cAMP)-
receptor element binding protein (CREB)] and primary and
secondary transcription start sites. We found no mutations in
these promoter sequences in any of the 13 patients. In one three-
generation family, the absence of mutation was confirmed by
sequencing in two additional affected family members, and in
this family haplotype analysis excluded linkage to the region
of the CLCN5 gene. There were no differences between the 19
patients with CLCN5 mutations and the 13 without mutations
with regard to any clinical features of Dent’s disease.
Conclusion. These findings suggest that mutation in other
gene(s) may be responsible for the phenotype of Dent’s disease
in some patients.
Dent’s disease, also known as X-linked nephrolithiasis,
has been defined by a characteristic syndrome that distin-
guishes it clearly from other hereditary causes of Fanconi
syndrome, kidney stones, or renal failure [1–5]. The
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typical features include disturbed proximal tubular reab-
sorption [particularly low-molecular-weight (LMW)
proteinuria], hypercalciuria, nephrocalcinosis,
nephrolithiasis, renal failure, and rickets. The gene,
CLCN5, encoding the voltage-gated chloride channel
ClC-5, was identified through positional cloning in
American and English families [2, 3, 6]. Mutations that
inactivate function of this channel have been identified in
every reported family with Dent’s disease, and mutations
segregate with the disease in each family [2, 7–16].
Most of the clinical features of the human disease are
reproduced in the mouse when expression of the CLCN5
is inactivated [17–20]. This evidence establishes a causal
relationship between inactivating mutations in CLCN5
and Dent’s disease.
We have performed mutation analysis in probands in 32
families who met strict clinical criteria for the diagnosis of
Dent’s disease. In 13 of these families, we found no muta-
tion, and we pursued additional studies that revealed the
first evidence of genetic heterogeneity in Dent’s disease.
METHODS
Patients
Patients were identified and brought to the investiga-
tors’ attention by the physicians involved in their care
(Table 1). The diagnosis of Dent’s disease (X-linked
nephrolithiasis) was based on the presence of all three
of the following criteria: (1) LMW proteinuria [exces-
sive excretion of b 2-microglobulin and/or retinol binding-
protein (RBP)]; (2) hypercalciuria; and (3) at least one
of the following: nephrocalcinosis, nephrolithiasis, hema-
turia, hypophosphatemia, or renal insufficiency.
LMW proteinuria was defined as an elevation in the
excretion of either b 2-microglobulin or RBP, expressed
either per 24 hours or per mg creatinine, by at least five-
fold above the upper limit of normal for that labora-
tory. In all cases in which both proteins were measured,
both met this criterion. Hypercalciuria was defined as
>4 mg/kg in a 24-hour collection or >0.25 mg calcium per
mg creatinine on a spot specimen (all patients collected
24-hour specimens except for six young boys). Nephrocal-
cinosis was determined radiographically, in most cases by
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Table 1. Physicians and patient locations
Patient Age (years) Physician Location
1 15 Andrew Brem, M.D. Brown University, Providence, RI
2 13 David Kenagy, M.D. United States Air Force, Dayton, OH
3 7.5 Douglas Blowey, M.D. The Children’s Mercy Hospital, Kansas City, MO
4 10 Avi Katz, M.D. University of Minnesota, Minneapolis, MN
5 39 Sharon Moe, M.D. University of Indiana, Indianapolis, IN
6 6 Valerie Langlois, M.D. Loyola University, Chicago, IL
7 3 Ronald Hogg, M.D. Dallas, TX
8 16 Scott VanWhy, M.D. Yale University, New Haven, CT
9 17 Michael Freundlich, M.D. University of Miami, Miami, FL
10 13 Scott VanWhy, M.D. Yale University, New Haven, CT
11 6 Barbara Botelho, M.D. Children’s Hospital, Oakland, CA
12 18 Beth Vogt, M.D. Rainbow Children’s Hospital, Cleveland, OH
13 2.5 William Primack, M.D. University of Massachusetts, Worcester, MA
14 13 Robert Holleman, M.D. Mary Bridge Children’s Hospital, Tacoma, WA
15 5.5 Michael Whyte, M.D. Shriners’ Hospital for Children, St. Louis, MO
16 2 B. Toenshoff, M.D., S. Haas, M.D. University Children’s Hospital, Heidelberg, Germany
17 4.5 Ronald Hogg, M.D. Dallas, TX
18 6 Beth Vogt, M.D. Rainbow Children’s Hosp., Cleveland OH
19 12 Michael Somers, M.D. Boston Children’s Hosp., Boston, MA
20 9 B. Toenshoff, M.D., S. Haas, M.D. University Children’s Hospital, Heidelberg, Germany
21 17 B. Toenshoff, M.D., S. Haas, M.D. University Children’s Hospital, Heidelberg, Germany
22 7 Craig Langman, M.D. Northwestern University, Chicago, IL
23 4 Douglas Blowey, M.D. The Children’s Mercy Hospital, Kansas City, MO
24 22 Janos Matyus, M.D., Ph.D. Universotu of Debrecen Medical School, Hungary
25 8 Bernd Hoppe, M.D. University of Cologne, Germany
26 9 Ari Simckes, M.D. The Children’s Mercy Hospital, Kansas City, MO
27 15 Horacio Lejarraga, M.D. Hospital Garrahan, Buenos Aires, Argentina
28 3 William G. Conley, III, M.D. University of North Carolina, Chapel Hill, NC
29 10 Velibor Tasik, M.D., Ph.D. Clinic for Children’s Diseases, Skopje, Macedonia
30 10 Craig Langman, M.D. Northwestern University, Chicago, IL
31 (infancy) Fatih Ozaltin, M.D. Hacettepe University Faculty of Medicine, Ankara, Turkey
32 9 Robert Holleman, M.D. Mary Bridge Children’s Hospital, Tacoma, WA
ultrasonography. The presence of rickets was determined
by radiographic features, and when these were absent the
patient was labeled as lacking rickets. Renal failure was
defined as a creatinine clearance below the published lim-
its of normal for age [21] or a serum creatinine above
the age-related normal ranges of Schwartz, Brion, and
Spitzer [22]. Patients were excluded if they had any clini-
cal evidence for other possible causes of proximal tubular
dysfunction, hypercalciuria, or renal failure.
Probands from 35 unrelated families met the inclusion
criteria for the study. Two were excluded because mea-
surements of leukocyte cystine levels were elevated. One
was excluded because of clinical features of Lowe’s syn-
drome. The remaining 32 probands were studied.
Mutation analysis
Genomic DNA was isolated from peripheral leuko-
cytes, and sequencing of the coding sequence of CLCN5
from genomic DNA was performed as previously de-
scribed [23]. The primers used allowed examination of
flanking intronic sequence harboring splice sites. In each
subject whose coding sequence was normal, we also se-
quenced two regions of the CLCN5 promoter (626 and
586 bp, respectively 2.1 and 1 kb upstream of exon 2) con-
taining regulatory sites [activating protein-1 (AP-1)-like,
AP-4, and cyclic adenosine monophosphate (cAMP)-
receptor element binding protein (CREB)] and primary
and secondary transcription start sites (Fig. 1). Primer se-
quences for sequencing the promoter regions were: exon
1a left, 5′-CTT TTG CCA TTT CCT TGC TTC TCT T-
3′; right, 5′-AGC CCG CAT TTG GTC ATT CAG GTT
3′; and exon 1b left 5′-TCT CCC CCA TTC CCA CCG
TTC AT-3′; right 5′-GGA GGT TGG AGC AGC TTA
GGT ATT T-3′.
When a mutation resulted in alteration in a restriction
enzyme recognition site, that mutation was confirmed by
restriction analysis, and this was also used to screen other
members of the family; when no restriction site change
resulted, the mutation was confirmed, and other family
members screened, by repeat sequencing of the appropri-
ate exon and by allele-specific polymerase chain reaction
(PCR). A panel of DNA representing 126 unrelated chro-
mosomes from normal individuals was screened for each
mutation by restriction analysis or allele-specific PCR.
Allele-specific PCR was performed according to the
method of Bottema and Sommer [24]. Primer pairs were
designed to have a melting temperature (Tm) of approxi-
mately 48◦C, with the last base at the 3′ end of one primer
matching the mutation to be tested. Primers were chosen
to produce a product size of approximately 150 to 200
bp. Thermocycler conditions were 46 cycles of 94◦C for
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Fig. 1. CLCN5 gene promoter region. Major
promoter activity maps to the 5′ region of exon
la, while a weaker promoter maps to the 5′ re-
gion of exon lb (bold arrows). Possible regu-
latory protein binding regions are labeled, 5′
of the transcription start sites. Double arrows
indicate regions of the promoters that were
sequenced (not to scale) [36].
Table 2. Mutations in 19 patients with Dent’s disease
Restriction
Patient Base change Mutation Helix enzyme
Missense mutations
1 TGT→CGT C221R F Btg I
2 TCG→TTG S244L G –
3 TCG→TTG S244L G –
4 TCG→TTG S244L G –
5 GAA→GCA E267A H Ear I
6 AGC→GGC S270G H-to-I loop Alu I
7 GGT→GAT G462D N SfaN I
8 GGG→AGG G513R O Aar I
9 CGG→TGG R516W O-to-P loop Hinf I
10 AGC→AAC S545N Q –
11 AAG→GAG K546E Q –
12 ACT→AGT T657S C-terminal loop –
Nonsense mutations
13 TGG→TAG W45X Sau96 I
14 TGT→TGA C221X Dde I
15 CGA→TGA R347X –
16 CGA→TGA R718X Hph I
17 CGA→TGA R718X Hph I
Frameshift mutations
18 CCC→CC− C del 687fs
19 ACA→TACA T ins 694fs
1 minute, 50◦C for 2 minutes, and 72◦C for 3 minutes.
Positive control samples of genomic DNA with the mu-
tation, without the mutation and a heterozygote (or 1:2
diluted mutation containing DNA) were included with
each assay (an additional pair of primers that always pro-
duced a unique band was added to the PCR reaction to
serve as an internal positive control for the PCR). PCR
products were separated and visualized on an ethidium
bromide-containing agarose gel.
Haplotype analysis
Five microsatellite markers were used for haplo-
type analysis of the region of the CLCN5 gene.
These were [in order (NCBI human map release build
30)]: telomere-DXS8042-DXS1201-DXS1055-CLCN5-
DXS1039-DXS988-centromere, spanning a region of ap-
proximately 16 cM or 14 Mb. Genomic DNA was used
in the PCR with primers for each of these markers (Re-
search Genetics) amplified under conditions as recom-
mended by the supplier. Alleles were identified by PCR
product sizes following separation on 8% polyacrylamide
gels.
RESULTS
Mutations
The 16 mutations identified in 19 families are indicated
on Table 2. These included 10 missense mutations (in 12
unrelated patients), in which a single base change pre-
dicts substitution of an amino acid in a conserved re-
gion of the protein. Two of these mutations (S244L and
R516W) have been previously reported [2, 7] and found
not to occur in normal subjects. We studied the other
eight mutations and found none of them in 126 chromo-
somes from normal individuals, indicating that these are
not mere polymorphisms.
In addition, we identified four nonsense mutations
(in five patients) and two frameshift mutations (in two
patients) predicted to result in premature termination
of translation. These also would be expected to inac-
tivate channel function. One of the nonsense muta-
tions (R347X) was previously reported in a Japanese
family [13]. In each of our families for which samples
were available, the mutation segregated with disease,
and the mother of the proband was heterozygous for the
mutation.
In one patient with a mutation in CLCN5, we also iden-
tified a silent polymorphism, a C to T transition in codon
568 (CCC → CCT) that predicts no change in the en-
coded amino acid (proline). One other silent polymor-
phism (codon 484) has previously been reported [7].
Thirteen subjects had a normal coding sequence for
CLCN5. In all 13 probands with normal CLCN5 coding
sequence, the promoter regions were sequenced and also
found to be normal.
Haplotype analysis
The family of patient 24 included five available affected
males. We repeated sequencing of the coding and pro-
moter regions of CLCN5 in two other affected males
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Table 3. Haplotype analysis in five affected and three unaffected
males in the family of patient 24
Affected males Unaffected males
Subject A B C D E F G
Locus
Telomere
DXS8042 2 4 4 4 4 3 2
DXS1201 3 4 4 4 4 3 3
DXS1055 3 2 2 2 2 2 3
CLCN5
DXS1039 1 1 1 2 2 2 1
DXS988 1 1 1 2 2 1 2
Centromere
Table 4. Clinical features in patients with and without mutations
With Without
mutations mutation v 2 P
Nephrocalcinosis 17/19 8/12 2.451 0.117
Stones 5/17 1/12 1.905 0.168
Renal failure 5/19 4/12 0.176 0.675
Hypophosphatemia 9/18 7/12 0.201 0.654
Hematuria 16/19 7/11 1.648 0.199
Aminoaciduria 6/8 5/10 1.169 0.280
Glycosuria 7/18 4/11 0.018 0.892
Rickets 5/13 3/11 0.336 0.562
Hypokalemia 6/17 1/13 3.137 0.077
Hypomagnesemia 2/13 1/9 0.082 0.774
Comparisons performed using Pearson’s chi-square test of independence.
who met criteria for Dent’s disease (in addition to the
proband) and confirmed that these were normal. Hap-
lotype analysis in the five affected males and three unaf-
fected males excluded linkage to the region of the CLCN5
gene (Table 3).
Clinical features
Every proband in this study met the same inclusion and
exclusion criteria for the diagnosis for Dent’s disease. Ad-
ditional data regarding clinical features are given in Table
4. In the group overall, the prevalence of nephrocalci-
nosis (81%), nephrolithiasis (21%), renal failure (29%),
hypophosphatemia (53%), rickets (33%), and other fea-
tures of the disease was similar to those we have previ-
ously reported [25]. There was no difference in any of
these features between the groups with and without mu-
tations. The ages of patients (Table 1) were no different
in those with (11.0 ± 2.0 years) and without mutations
(10.3 ± 1.6 years) (mean ± SE). Renal failure was present
in none of the 17 patients under the age of 10 years in ei-
ther group, but among patients age 10 years and older,
renal failure was present in five of ten patients with mu-
tations and in four of five without mutations. We have
reported that nephrocalcinosis is found only occasionally
in boys before the teenage years [3, 4], but in this study
nephrocalcinosis was present in all of the 11 patients un-
der the age of 7 years in both groups (eight with mutations
and three without). White blood cell cystine levels were
measured and found to be normal in all 6 of the tested
probands lacking mutation in CLCN5, and slit-lamp eye
examinations were normal in three additional patients
without mutations.
DISCUSSION
Until this report, a total of 54 mutations had been
reported in 71 families with Dent’s disease, including
missense, nonsense, frameshift, splice-site, in-frame inser-
tion, and microdeletion mutations [2, 7–16, 26–29]. The
16 mutations identified in our 19 patients with Dent’s dis-
ease represent the largest single published collection of
mutations. They bring the total number of reported mu-
tations to 68 in 90 families.
One of these mutations, S244L, has been reported in
four other families in addition to the three described here
[2, 10, 16, 23], and this is the most common mutation
in CLCN5 thus far described. Lloyd et al [2] expressed
the S244L mutation in Xenopus and demonstrated that
it substantially reduces the chloride conductance of the
channel. The nonsense R347X mutation has also been
expressed and found to inactivate function of the chloride
channel [13].
Nine of the ten missense mutations described here
occur within (C221R, S244L, G462D, G513R, S545N,
K546E, and E267A) or near (S270G and R516W) trans-
membrane domains. The T657 mutation occurs in the C-
terminal cytoplasmic domain within ten amino acids of
a PY domain that appears to be an internalization sig-
nal that interacts with ubiqitin-protein ligases [30]. The
functional effects of this specific mutation have not been
studied.
Wu et al [31] have analyzed the previously reported
mutations relative to the recent characterization of
the 3-dimensional structure of bacterial ClCs reported
by Dutzler et al [32]. Table 2 indicates the position of
each of the missense mutations we found in our patients
relative to this model; the transmembrane domains are
identified using letters as assigned by Wu et al. ClC chlo-
ride channels are homodimers, and helices H, I, P and Q
are the major helices involved in establishing the dimer
interface [31]; mutations E267A (helix H), S545N and
K546E (both helix Q) are in these domains. Helices D, F,
N, and R come together to form the chloride-selectivity
filter near the center of the channel. Mutations C221R
(helix F) and G462D (helix N) are the first mutations
reported in these helices.
Another 13 patients met the same entry criteria for the
diagnosis of Dent’s disease, yet lacked any mutation in the
coding sequence for CLCN5. No mutations in promoter
regions for this gene have been reported. We sequenced
the two promoter regions in each of these 13 subjects,
and found no mutations. The presence of a family history
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of renal failure, kidney stones, or other features of this
disease in three of these subjects indicated that the dis-
ease occurred on a familial rather than a sporadic ba-
sis. In the one family large enough to perform haplotype
analysis, we excluded linkage to the region of the X chro-
mosome harboring the CLCN5 gene. A comparison of
clinical findings between patients with mutations and
those lacking mutations indicated no difference between
the two groups, although the power of this analysis to
detect a difference is limited by the small numbers of
patients. This evidence suggests that there is genetic het-
erogeneity in Dent’s disease.
The voltage-gated chloride channel ClC-5 is expressed
in the kidney in subapical endosomes of the cells of the
proximal tubule and the medullary thick ascending limb
of Henle’s loop. Dysfunction of proximal tubular endo-
somes is consistent with the nearly universal finding of
LMW proteinuria. Consequent abnormalities in mem-
brane recycling could explain other defects in proximal
tubular function such as phosphaturia, aminoaciduria,
and glycosuria. Abnormal trafficking of the sodium-
phosphate cotransporter NaPi2 [18] and of megalin and
cubulin [33] has been observed in CLCN5 knockout mice,
and the low urinary levels of megalin observed in knock-
out mice [18] and in patients with Dent’s disease [34]
would also be consistent with abnormal membrane recy-
cling. Other important features of Dent’s disease, includ-
ing absorptive hypercalciuria (possiby the consequence
of excessive production of 1,25-dihydroxyvitamin D by
renal epithelial cells), and renal failure, remain unex-
plained. If the ClC-5 chloride channel is intact in some
patients with Dent’s disease, it is reasonable to specu-
late that the phenotype could be produced by defects of
other proteins necessary for endosomal function in the
proximal tubular epithelium. In these cells, the chloride
channel is thought to provide a voltage shunt that al-
lows maximal acidification of the endosomal lumen, ac-
complished through a proton-andenosine triphosphatase
(ATPase). The endosomal proton-ATPase is a complex
multimeric protein consisting of 13 subunit types, and
these ATPase subunits could be important candidates
for Dent’s disease in these patients. To date, no proton
ATPase subunit has been found to be expressed predomi-
nantly in proximal tubule. Other candidates could include
proteins involved in regulation, processing, or trafficking
of ClC-5 or other endosomal membrane components, or
any of a range of proteins that are necessary for normal
proximal tubular reabsorptive function. Identification of
other gene(s) that are mutated in patients with Dent’s
disease will require mapping work in families.
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